PE20220708A1 - Anticuerpos anti-cd73 - Google Patents
Anticuerpos anti-cd73Info
- Publication number
- PE20220708A1 PE20220708A1 PE2022000364A PE2022000364A PE20220708A1 PE 20220708 A1 PE20220708 A1 PE 20220708A1 PE 2022000364 A PE2022000364 A PE 2022000364A PE 2022000364 A PE2022000364 A PE 2022000364A PE 20220708 A1 PE20220708 A1 PE 20220708A1
- Authority
- PE
- Peru
- Prior art keywords
- seq
- amino acid
- acid sequences
- antibody
- nos
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y301/00—Hydrolases acting on ester bonds (3.1)
- C12Y301/03—Phosphoric monoester hydrolases (3.1.3)
- C12Y301/03005—5'-Nucleotidase (3.1.3.5)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Epidemiology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962896908P | 2019-09-06 | 2019-09-06 | |
| PCT/EP2020/074804 WO2021044005A1 (en) | 2019-09-06 | 2020-09-04 | Anti-cd73 antibodies |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20220708A1 true PE20220708A1 (es) | 2022-05-04 |
Family
ID=72517218
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2022000364A PE20220708A1 (es) | 2019-09-06 | 2020-09-04 | Anticuerpos anti-cd73 |
Country Status (18)
| Country | Link |
|---|---|
| US (2) | US11634500B2 (https=) |
| EP (1) | EP4025605A1 (https=) |
| JP (1) | JP7662617B2 (https=) |
| KR (1) | KR20220057558A (https=) |
| CN (1) | CN115023439B (https=) |
| AU (1) | AU2020342778A1 (https=) |
| BR (1) | BR112022003956A2 (https=) |
| CA (1) | CA3153213A1 (https=) |
| CL (1) | CL2024002093A1 (https=) |
| CO (1) | CO2022002622A2 (https=) |
| IL (1) | IL291068A (https=) |
| MX (1) | MX2022002682A (https=) |
| MY (1) | MY207784A (https=) |
| PE (1) | PE20220708A1 (https=) |
| PH (1) | PH12022550509A1 (https=) |
| TW (1) | TWI859319B (https=) |
| UA (1) | UA130408C2 (https=) |
| WO (1) | WO2021044005A1 (https=) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PE20221409A1 (es) | 2020-01-03 | 2022-09-20 | Incyte Corp | Anticuerpos anti-cd73 y usos de estos |
| TW202135823A (zh) | 2020-01-03 | 2021-10-01 | 美商英塞特公司 | Ｃｄ７３抑制劑及ａ２ａ／ａ２ｂ腺苷受體抑制劑組合療法 |
| JP2023532234A (ja) * | 2020-06-22 | 2023-07-27 | イノベント バイオロジクス（スーチョウ）カンパニー，リミティド | 抗ｃｄ７３抗体とその用途 |
| GB202105110D0 (en) * | 2021-04-09 | 2021-05-26 | Cancer Research Tech Ltd | Anti-CD73 antibodies |
| JP2025512384A (ja) | 2022-04-13 | 2025-04-17 | ギリアード サイエンシーズ， インコーポレイテッド | Ｔｒｏｐ－２発現がんを治療するための併用療法 |
| CN117304316A (zh) * | 2022-06-22 | 2023-12-29 | 复旦大学 | 靶向cd73的纳米抗体及纳米抗体-药物偶联物、其制备方法和用途 |
| WO2024040194A1 (en) | 2022-08-17 | 2024-02-22 | Capstan Therapeutics, Inc. | Conditioning for in vivo immune cell engineering |
| CN116178546B (zh) * | 2022-10-13 | 2024-06-18 | 深圳市百士通科技开发有限公司 | 一种多功能重组抗体及其制备方法和应用 |
| AU2024279278A1 (en) | 2023-05-31 | 2025-12-18 | Capstan Therapeutics, Inc. | Lipid nanoparticle formulations and compositions |
| WO2025076113A1 (en) | 2023-10-05 | 2025-04-10 | Capstan Therapeutics, Inc. | Ionizable cationic lipids with conserved spacing and lipid nanoparticles |
| US20250127728A1 (en) | 2023-10-05 | 2025-04-24 | Capstan Therapeutics, Inc. | Constrained Ionizable Cationic Lipids and Lipid Nanoparticles |
| WO2025135233A1 (ko) * | 2023-12-21 | 2025-06-26 | ㈜지아이이노베이션 | Cd73에 특이적으로 결합하는 항체 및 이의 용도 |
| WO2025137640A1 (en) | 2023-12-22 | 2025-06-26 | Gilead Sciences, Inc. | Azaspiro wrn inhibitors |
| US20250302763A1 (en) | 2024-02-22 | 2025-10-02 | Capstan Therapeutics, Inc. | Immune engineering amplification |
| WO2025217452A1 (en) | 2024-04-11 | 2025-10-16 | Capstan Therapeutics, Inc. | Constrained ionizable cationic lipids and lipid nanoparticles |
| WO2025217454A2 (en) | 2024-04-11 | 2025-10-16 | Capstan Therapeutics, Inc. | Ionizable cationic lipids and lipid nanoparticles |
Family Cites Families (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US338841A (en) | 1886-03-30 | herden | ||
| US256055A (en) | 1882-04-04 | Compound engine | ||
| US323997A (en) | 1885-08-11 | Machine-gun | ||
| US4634665A (en) | 1980-02-25 | 1987-01-06 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US5179017A (en) | 1980-02-25 | 1993-01-12 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US4399216A (en) | 1980-02-25 | 1983-08-16 | The Trustees Of Columbia University | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US4510245A (en) | 1982-11-18 | 1985-04-09 | Chiron Corporation | Adenovirus promoter system |
| US4740461A (en) | 1983-12-27 | 1988-04-26 | Genetics Institute, Inc. | Vectors and methods for transformation of eucaryotic cells |
| US5168062A (en) | 1985-01-30 | 1992-12-01 | University Of Iowa Research Foundation | Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence |
| EP0216846B2 (en) | 1985-04-01 | 1995-04-26 | Celltech Limited | Transformed myeloma cell-line and a process for the expression of a gene coding for a eukaryotic polypeptide employing same |
| US4968615A (en) | 1985-12-18 | 1990-11-06 | Ciba-Geigy Corporation | Deoxyribonucleic acid segment from a virus |
| US4959455A (en) | 1986-07-14 | 1990-09-25 | Genetics Institute, Inc. | Primate hematopoietic growth factors IL-3 and pharmaceutical compositions |
| US4912040A (en) | 1986-11-14 | 1990-03-27 | Genetics Institute, Inc. | Eucaryotic expression system |
| EP1105427A2 (en) | 1998-08-17 | 2001-06-13 | Abgenix, Inc. | Generation of modified molecules with increased serum half-lives |
| WO2000067796A1 (en) | 1999-05-07 | 2000-11-16 | Genentech, Inc. | Treatment of autoimmune diseases with antagonists which bind to b cell surface markers |
| US6517529B1 (en) | 1999-11-24 | 2003-02-11 | Radius International Limited Partnership | Hemodialysis catheter |
| AU2001259142C1 (en) | 2000-04-25 | 2006-11-23 | Biogen Idec Inc. | Intrathecal administration of rituximab for treatment of central nervous system lymphomas |
| WO2004079013A1 (en) | 2003-03-03 | 2004-09-16 | Arizona Board Of Regents On Behalf Of The University Of Arizona | Ecto-5’-nucleotidase (cd73) used in the diagnosis and the treatment of pancreatic cancer |
| EP1613350B1 (en) | 2003-04-09 | 2009-03-18 | Genentech, Inc. | Therapy of autoimmune disease in a patient with an inadequate response to a tnf-alpha inhibitor |
| WO2006113181A2 (en) | 2005-04-08 | 2006-10-26 | University Of Florida Research Foundation, Inc. | Stem-like cells in bone sarcomas |
| WO2006125140A2 (en) | 2005-05-18 | 2006-11-23 | Biogen Idec Inc. | Methods for treating fibrotic conditions |
| ES2618543T3 (es) | 2005-11-23 | 2017-06-21 | Genentech, Inc. | Métodos y composiciones relacionados con ensayos de linfocitos B |
| US8975081B2 (en) | 2007-10-24 | 2015-03-10 | Faron Pharmaceuticals Oy | Biomarker for monitoring development of diseases and assessing the efficacy of therapies |
| EP2593595B1 (en) * | 2010-07-16 | 2020-03-11 | Avantgen, Inc. | Novel peptides and uses thereof |
| WO2014153424A1 (en) | 2013-03-19 | 2014-09-25 | La Jolla Institute For Allergy And Immunology | Reducing diabetes in patients receiving hmg-coa reductase inhibitors (statins) |
| JP2017514458A (ja) * | 2014-03-12 | 2017-06-08 | プロセナ バイオサイエンシーズ リミテッド | Ｌｇ４−５に対して特異的な抗−ラミニン４抗体 |
| US20180030144A1 (en) | 2014-10-10 | 2018-02-01 | Innate Pharma | Cd73 blockade |
| EP3204417B1 (en) | 2014-10-10 | 2020-07-22 | Innate Pharma | Cd73 blockade |
| GB2537445A (en) | 2014-11-10 | 2016-10-19 | Medimmune Ltd | Binding molecules specific for CD73 and uses thereof |
| GB2538120A (en) | 2014-11-11 | 2016-11-09 | Medimmune Ltd | Therapeutic combinations comprising anti-CD73 antibodies and uses thereof |
| AU2015349878A1 (en) | 2014-11-21 | 2017-05-25 | Bristol-Myers Squibb Company | Antibodies against CD73 and uses thereof |
| CA2988119A1 (en) | 2015-06-03 | 2016-12-08 | Dana-Farber Cancer Institute, Inc. | Methods to induce conversion of regulatory t cells into effector t cells for cancer immunotherapy |
| JOP20160154B1 (ar) * | 2015-07-31 | 2021-08-17 | Regeneron Pharma | أجسام ضادة مضاد لل psma، وجزيئات رابطة لمستضد ثنائي النوعية الذي يربط psma و cd3، واستخداماتها |
| ES2924402T3 (es) | 2015-10-02 | 2022-10-06 | Symphogen As | Anticuerpos anti-PD-1 y composiciones |
| US11130817B2 (en) | 2015-10-12 | 2021-09-28 | Innate Pharma | CD73 blocking agents |
| CN114805575B (zh) | 2015-12-09 | 2024-07-23 | 科尔沃斯制药股份有限公司 | 人源化抗cd73抗体 |
| US20200232974A1 (en) | 2016-03-30 | 2020-07-23 | Centre Léon-Bérard | Lymphocytes expressing cd73 in cancerous patient dictates therapy |
| WO2018013611A1 (en) | 2016-07-11 | 2018-01-18 | Corvus Pharmaceuticals, Inc. | Anti-cd73 antibodies |
| JP7066690B2 (ja) * | 2016-09-23 | 2022-05-13 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | 抗ｍｕｃ１６（ムチン１６）抗体 |
| PH12019500668B1 (en) * | 2016-10-13 | 2023-12-06 | Chia Tai Tianqing Pharmaceutical Group Co Ltd | Anti-lag-3 antibodies and compositions |
| CA3045376C (en) | 2017-01-24 | 2022-08-30 | I-Mab | Anti-cd73 antibodies and uses thereof |
| US20210107989A1 (en) | 2017-04-04 | 2021-04-15 | Corvus Pharmaceuticals, Inc. | Methods for treating cd73hi tumors |
| US11530273B2 (en) | 2017-05-23 | 2022-12-20 | Helmholtz Zentrum München—Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) | Anti-CD73 monoclonal antibody, encoding nucleic acids and method for producing |
| MY204117A (en) | 2017-06-22 | 2024-08-08 | Novartis Ag | Antibody molecules to cd73 and uses thereof |
| WO2019173692A2 (en) | 2018-03-09 | 2019-09-12 | Agenus Inc. | Anti-cd73 antibodies and methods of use thereof |
-
2020
- 2020-09-04 UA UAA202201023A patent/UA130408C2/uk unknown
- 2020-09-04 EP EP20772002.0A patent/EP4025605A1/en active Pending
- 2020-09-04 WO PCT/EP2020/074804 patent/WO2021044005A1/en not_active Ceased
- 2020-09-04 CN CN202080076881.9A patent/CN115023439B/zh active Active
- 2020-09-04 KR KR1020227010511A patent/KR20220057558A/ko active Pending
- 2020-09-04 AU AU2020342778A patent/AU2020342778A1/en active Pending
- 2020-09-04 PE PE2022000364A patent/PE20220708A1/es unknown
- 2020-09-04 MY MYPI2022001106A patent/MY207784A/en unknown
- 2020-09-04 US US17/012,942 patent/US11634500B2/en active Active
- 2020-09-04 CA CA3153213A patent/CA3153213A1/en active Pending
- 2020-09-04 PH PH1/2022/550509A patent/PH12022550509A1/en unknown
- 2020-09-04 BR BR112022003956A patent/BR112022003956A2/pt unknown
- 2020-09-04 MX MX2022002682A patent/MX2022002682A/es unknown
- 2020-09-04 TW TW109130508A patent/TWI859319B/zh active
- 2020-09-04 JP JP2022514681A patent/JP7662617B2/ja active Active
-
2022
- 2022-03-02 IL IL291068A patent/IL291068A/en unknown
- 2022-03-04 CO CONC2022/0002622A patent/CO2022002622A2/es unknown
-
2023
- 2023-03-17 US US18/185,848 patent/US20230227573A1/en active Pending
-
2024
- 2024-07-10 CL CL2024002093A patent/CL2024002093A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| MX2022002682A (es) | 2022-04-07 |
| AU2020342778A1 (en) | 2022-03-31 |
| PH12022550509A1 (en) | 2023-03-20 |
| WO2021044005A1 (en) | 2021-03-11 |
| CN115023439A (zh) | 2022-09-06 |
| US11634500B2 (en) | 2023-04-25 |
| CO2022002622A2 (es) | 2022-04-08 |
| JP7662617B2 (ja) | 2025-04-15 |
| KR20220057558A (ko) | 2022-05-09 |
| US20210070876A1 (en) | 2021-03-11 |
| IL291068A (en) | 2022-05-01 |
| BR112022003956A2 (pt) | 2022-05-24 |
| UA130408C2 (uk) | 2026-02-11 |
| JP2022547081A (ja) | 2022-11-10 |
| US20230227573A1 (en) | 2023-07-20 |
| TWI859319B (zh) | 2024-10-21 |
| MY207784A (en) | 2025-03-18 |
| CN115023439B (zh) | 2026-04-03 |
| CL2024002093A1 (es) | 2024-12-27 |
| EP4025605A1 (en) | 2022-07-13 |
| NZ785824A (en) | 2025-10-31 |
| CA3153213A1 (en) | 2021-03-11 |
| TW202122423A (zh) | 2021-06-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20220708A1 (es) | Anticuerpos anti-cd73 | |
| PE20190975A1 (es) | Novela cd47 anticuerpos monoclonales y sus usos | |
| PE20200294A1 (es) | Anticuerpos que se unen especificamente a pd-1 y metodos de uso | |
| PE20210132A1 (es) | Anticuerpos anti-cd3 y usos de estos | |
| PE20110306A1 (es) | Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) | |
| CL2020001974A1 (es) | Anticuerpos anti-trem2 y métodos para utilizarlos. (divisional solicitud 201903093) | |
| PE20120340A1 (es) | Combinaciones antitumorales que contienen anticuerpos que reconocen especificamente cd38 y melfalan | |
| EA201991577A1 (ru) | Новые антитела против рецептора трансферрина человека, способные преодолевать гематоэнцефалический барьер | |
| PE20200011A1 (es) | ANTICUERPOS ANTI-PEPTIDO BETA AMILOIDE N3pGlu Y SUS USOS | |
| MX2019010282A (es) | Formulacion de anticuerpos monoclonales. | |
| MX2021011167A (es) | Anticuerpos humanizados anti grupo de diferenciacion 19 (cd19) humano y metodos de uso. | |
| ES2687282T3 (es) | Anticuerpos humanizados ANTI-CD134 (OX40) y sus usos | |
| PE20181921A1 (es) | NUEVOS ANTICUERPOS ANTI-SIRPa Y SUS APLICACIONES TERAPEUTICAS | |
| GT200600182A (es) | Anticuerpos dirigidos contra el peptido amiloide beta y metodo que utilizan los mismos | |
| ES2572177T3 (es) | Anticuerpos neutralizantes anti-B7RP1 humanos | |
| EA202190335A1 (ru) | Композиции антител против fcrn и способы их применения | |
| PE20141151A1 (es) | Proteinas de union al antigeno cd27l | |
| PE20130817A1 (es) | Anticuerpos peptidicos beta amiloide anti-n3pglu y usos de los mismos | |
| PE20191079A1 (es) | Inmunoglobulinas y usos de estas | |
| PE20170665A1 (es) | Anticuerpos anti-tau humanizados | |
| AR109715A1 (es) | Anticuerpos anti-cd27 | |
| CO6180445A2 (es) | Anticuerpos agonistas anti notch3 y su uso en el tratamiento de las enfermedades relacionadas con el gen notch3 | |
| PE20211708A1 (es) | Tratamiento de cefalea por uso excesivo de medicamentos usando anticuerpos anticgrp o anti-cgrp-r | |
| NZ594682A (en) | Fully human antibodies specific to cadm1 | |
| CL2020002600A1 (es) | Anticuerpo anti-muerte programada-ligando 1 y su uso |